Patents Examined by Amy E Juedes
-
Patent number: 11976134Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-MUC16 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.Type: GrantFiled: February 4, 2022Date of Patent: May 7, 2024Assignee: PRECIGEN, INC.Inventors: Helen Sabzevari, Rutul Shah
-
Patent number: 11975029Abstract: Disclosed herein are compositions, methods, and kits for use in treating hematopoietic malignancies, the compositions, methods, and kits comprise a cytotoxic agent targeting cells expressing a lineage-specific cell-surface protein and a population of hematopoietic cells that express the lineage-specific cell-surface protein, the hematopoietic cells being manipulated such that they do not bind the cytotoxic agent.Type: GrantFiled: February 28, 2018Date of Patent: May 7, 2024Assignee: VOR BIOPHARMA INC.Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
-
Patent number: 11970545Abstract: A trifunctional molecule comprising a target-specific ligand, a ligand that binds a protein associated with the TCR complex and a T cell receptor signaling domain polypeptide is provided. The ligand that binds a protein associated with a TCR complex is UCHT1 with a Y182T mutation. Engineering T cells with this novel receptor engenders antigen specific activation of numerous T cell functions, including cytokine production, degranulation and cytolysis.Type: GrantFiled: March 22, 2023Date of Patent: April 30, 2024Assignee: McMaster UniversityInventors: Christopher W. Helsen, Jonathan Bramson, Anna Dvorkin-Gheva, Galina F. Denisova, Ksenia Bezverbnaya, Kenneth Anthony Mwawasi
-
Patent number: 11965173Abstract: There is provided a plasmid system for transfection into a cell to create a producer cell, the system comprising: a. a helper plasmid comprising a first nucleotide sequence encoding Murine leukemia virus (MLV)-derived Gag and Pol poly-proteins; b. an envelope plasmid comprising a second nucleotide sequence encoding an Env protein; c. a genome plasmid comprising a third nucleotide sequence encoding a retroviral genome, wherein the first nucleotide sequence is codon-shuffled to remove any significant regions of homology with the third nucleotide sequence; and wherein the second nucleotide sequence is codon-optimised for expression in the producer cell.Type: GrantFiled: December 14, 2018Date of Patent: April 23, 2024Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Paulo Fernandes, Hanna Kymalainen, Ekaterini Kotsopoulou
-
Patent number: 11957717Abstract: The present invention provides an anti-human MSLN-specific antibody and an MSLN-targeting immune effector cell. Also provided is an MSLN-targeting chimeric antigen receptor modified T-cell prepared using the antibody and a use thereof.Type: GrantFiled: April 9, 2021Date of Patent: April 16, 2024Assignee: HRAIN BIOTECHNOLOGY CO., LTD.Inventors: Fei Huang, Tao Peng, Xuemei Zou, Pinglei Liu, Dachun Liu, Hui Huang
-
Patent number: 11957734Abstract: Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders.Type: GrantFiled: March 25, 2021Date of Patent: April 16, 2024Assignee: Baylor Research InstituteInventors: SangKon Oh, Sandra Zurawski, Hyemee Joo, Gerard Zurawski
-
Patent number: 11951130Abstract: The present invention relates to an antigen-binding molecule comprising a heavy chain variable region comprising a heavy-chain complementarity-determining region 1 (HCDR1) comprising an amino acid sequence represented by Sequence No. 1, an HCDR2 comprising an amino acid sequence represented by Sequence No. 2, and an HCDR3 comprising an amino acid sequence represented by Sequence No. 3; a light-chain variable region comprising a light-chain complementarity-determining region 1 (LCDR1) comprising an amino acid sequence represented by Sequence No. 4, an LCDR2 comprising an amino acid sequence represented by Sequence No. 5, and an LCDR3 comprising an amino acid sequence represented by Sequence No. 6; wherein the antigen-binding molecule is a T cell receptor (TCR); and to a cell line expressing the same.Type: GrantFiled: March 1, 2021Date of Patent: April 9, 2024Assignee: Eutilex Co., Ltd.Inventors: Byoung S. Kwon, Young Ho Kim, Kwang Hee Kim, Ji Won Chung, Young Gyoon Chang, Bo Rim Yi, Jung Yun Lee, Seung Hyun Lee, Sun Woo Im, Jin Kyung Choi, Hyun Tae Son, Eun Hye Yoo
-
Patent number: 11952423Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.Type: GrantFiled: May 16, 2023Date of Patent: April 9, 2024Assignees: MIE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroshi Shiku, Yasushi Akahori, Kento Tanaka, Ayaka Yatsu, Junya Ichikawa, Toshiaki Ohtsuka, Shiho Kozuma, Ryuji Hashimoto, Makiko Nakayama, Naoya Shinozaki, Kensuke Nakamura, Ichiro Watanabe, Shinji Furuzono
-
Patent number: 11952427Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.Type: GrantFiled: March 15, 2022Date of Patent: April 9, 2024Assignees: Bristol-Myers Squibb Company, CytomX Therapeutics, Inc.Inventors: Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens, James William West
-
Patent number: 11944672Abstract: The gist of the invention consists in the therapeutic vaccine for treatment of diabetes type 1 in children, which contains Treg cells CD3(+)CD4(+)CD25(high)CD127(?). Claimed too is the cell sorter used to produce the vaccine and the method of multiplying Treg cells in vitro.Type: GrantFiled: December 22, 2017Date of Patent: April 2, 2024Assignee: Gdanski Uniwersytet MedycznyInventors: Piotr Trzonkowski, Malgorzata Mysliwiec, Natalia Marek-Trzonkowska
-
Patent number: 11945876Abstract: Some embodiments provided herein are chimeric costimulatory antigen receptor (CoStAR), useful in adoptive cell therapy (ACT), and cells comprising the CoStAR. In some embodiments, the CoStAR can act as a modulator of cellular activity enhancing responses to defined antigens. In some embodiments, CoStAR and/or fusion proteins, nucleic acids encoding the CoStAR and therapeutic uses thereof are also provided.Type: GrantFiled: June 15, 2022Date of Patent: April 2, 2024Assignees: Instil Bio (UK) Limited, Instil Bio, Inc.Inventors: John Bridgeman, Robert Hawkins, Ruben Rodriguez, Gray Kueberuwa, Milena Kalaitsidou
-
Patent number: 11945869Abstract: Provided herein are binding polypeptides that specifically bind PD-1. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs and chimeric antigen receptors, that bind PD-1. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided PD-1 binding polypeptides for treating diseases and conditions, such as cancer.Type: GrantFiled: November 11, 2021Date of Patent: April 2, 2024Assignee: Inhibrx, Inc.Inventors: Rajay A. Pandit, John C. Timmer, Angelica N. Sanabria, Florian Sulzmaier, Brendan P. Eckelman
-
Patent number: 11939388Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.Type: GrantFiled: June 28, 2021Date of Patent: March 26, 2024Assignees: GENMAB A/S, BioNTech SEInventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
-
Patent number: 11932871Abstract: Methods of culturing T cells are provided. Accordingly there is provided a method of culturing T cells comprising culturing T cells in the presence of a T cell stimulator, an exogenous CCL21 and an exogenous ICAM1, thereby culturing the T cells. Also provided are cell cultures, isolated T cells and uses of same.Type: GrantFiled: March 2, 2018Date of Patent: March 19, 2024Assignees: YEDA RESEARCH AND DEVELOPMENT CO. LTD., THE MEDICAL RESEARCH, INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTERInventors: Benjamin Geiger, Nir Friedman, Shimrit Lieber, Zelig Eshhar, Tova Waks, Anat Globerson Levin
-
Patent number: 11932686Abstract: The present invention relates to a novel use of regulatory T cell-specific surface protein Lrig-1, and more specifically to an immunosuppressive agent comprising siRNA which inhibits the expression of surface protein Lrig-1. In addition, the invention relates to a method for screening an immunosuppressive agent which inhibits proteins of Lrig-1 or genes encoding the proteins. As a result, an immunosuppressive agent with low side effects and high specificity can be developed.Type: GrantFiled: July 13, 2021Date of Patent: March 19, 2024Assignee: Good T Cells, Inc.Inventor: Sang-kyou Lee
-
Patent number: 11911414Abstract: The present is directed to compositions comprising regulatory T cell epitopes, wherein said epitopes comprises a polypeptide comprising at least a portion of SEQ NOS: 1-124 (and/or fragments and variants thereof), and optionally 1 to 12 additional amino acids distributed in any ratio on the N-terminus and/or C-terminus of the polypeptide of SEQ ID NOS: 1-124, as well as methods of producing and using the same.Type: GrantFiled: March 26, 2021Date of Patent: February 27, 2024Assignee: EpiVax Inc.Inventors: Anne De Groot, William Martin
-
Patent number: 11905529Abstract: The present disclosure provides for methods of improving the efficacy of T cells. In an aspect, the disclosure further provides for methods of enhancing the persistence of T cells for adoptive cell transfer or therapy (ACT). Cytokine sensitivity assays (CSA) and associated methodology capable of predicting the persistence of adoptively infused T Cells are further provided for by way of the instant disclosure. The disclosure also provides for methods of treating cancer in a subject in need thereof as well as T cells populations produced by methods described herein.Type: GrantFiled: October 2, 2020Date of Patent: February 20, 2024Assignee: Immatics US INC.Inventor: Amir Alpert
-
Patent number: 11897958Abstract: Described herein are monoclonal antibodies that bind to VSIG-4 including antibodies that block the binding of VSIG-4 to SIGLEC-7, compositions including the monoclonal antibodies, and methods of making and using those antibodies and compositions.Type: GrantFiled: August 19, 2020Date of Patent: February 13, 2024Assignee: BIO-TECHNE CORPORATIONInventors: Birte Aggeler, Christine Goetz, Jody Bonnevier, Christopher Carlin Valley, Christopher Hammerbeck, Ernesto Ruben Resnik
-
Patent number: 11897932Abstract: The present disclosure generally relates to, among other things, a new class of receptors engineered to modulate transcriptional regulation in a ligand-dependent manner. Particularly, the new receptors, even though derived from Notch, do not require the Notch negative regulatory regions previously believed to be essential for the functioning of the receptors. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various health conditions or diseases, such as cancers.Type: GrantFiled: March 30, 2021Date of Patent: February 13, 2024Assignee: The Regents of the University of CaliforniaInventors: Kole T. Roybal, Raymond Liu, Iowis Zhu
-
Patent number: 11897966Abstract: Disclosed herein are anti-mesothelin antibodies and antigen-binding fragments, chimeric antigen receptors (“CARs”) having these anti-mesothelin antibodies and antigen-binding fragments (“mesothelin CARs”) and genetically modified immune effector cells having such mesothelin CARs. Polynucleotides encoding the anti-mesothelin antibodies and antigen-binding fragments and mesothelin CARs are also provided herein. Compositions comprising anti-mesothelin antibodies and antigen-binding fragments and mesothelin CARs are also provided herein. The present disclosure also relates to uses of the anti-mesothelin antibodies and antigen-binding fragments and genetically modified immune effector cells having such mesothelin CARs in cancer treatment.Type: GrantFiled: December 6, 2022Date of Patent: February 13, 2024Assignee: UTC THERAPEUTICS (SHANGHAI) CO., LTD.Inventors: Yangbing Zhao, Gengzhen Zhu, Xiaojun Liu